Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. - Wikidata - awgldk - TriplyDB

Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.

Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.

http://www.wikidata.org/entity/Q45396940

about

Adefovir dipivoxil for adults with lamivudine-resistant chronic hepatitis B virus infection Interferon alpha for chronic hepatitis D Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation Hepatitis B and Delta Virus: Advances on Studies about Interactions between the Two Viruses and the Infected Hepatocyte Application of CRISPR/Cas9 Technology to HBV Animal models for the study of HCV Bacteriophages and their applications in the diagnosis and treatment of hepatitis B virus infection NTCP and beyond: opening the door to unveil hepatitis B virus entry Mouse models of hepatitis B virus infection comprising host-virus immunologic interactions Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments Hepatitis B: future curative strategies Usage of adenovirus expressing thymidine kinase mediated hepatocellular damage for enabling mouse liver repopulation with allogenic or xenogenic hepatocytes Cell therapy for the diseased liver: from stem cell biology to novel models for hepatotropic human pathogens Applications of human hepatitis B virus preS domain in bio- and nanotechnology.Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes Current and future antiviral drug therapies of hepatitis B chronic infection Stable Human Hepatoma Cell Lines for Efficient Regulated Expression of Nucleoside/Nucleotide Analog Resistant and Vaccine Escape Hepatitis B Virus Variants and Woolly Monkey Hepatitis B Virus Emerging antivirals for the treatment of hepatitis B.Interferon impedes an early step of hepatitis delta virus infection.Strategies to eliminate HBV infection.Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters.Solution structure and in silico binding of a cyclic peptide with hepatitis B surface antigen.PEGylation enables the specific tumor accumulation of a peptide identified by phage display.Proteoglycans act as cellular hepatitis delta virus attachment receptors.Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP).Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP).Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression Selection of HBV preS1-binding penta-peptides by phage display.Antiviral therapies and prospects for a cure of chronic hepatitis B.HBV life cycle: entry and morphogenesis.Endangered monkeys contribute to science.Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.Efficient Inhibition of Hepatitis B Virus Infection by a preS1-binding Peptide.Removing N-terminal sequences in pre-S1 domain enhanced antibody and B-cell responses by an HBV large surface antigen DNA vaccine.Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA.Mucroporin-M1 inhibits hepatitis B virus replication by activating the mitogen-activated protein kinase (MAPK) pathway and down-regulating HNF4α in vitro and in vivo N-Glycosylation of the Na+-Taurocholate Cotransporting Polypeptide (NTCP) Determines Its Trafficking and Stability and Is Required for Hepatitis B Virus Infection.Challenges in design and characterization of ligand-targeted drug delivery systems.

P2860

Q24187530-566C7CEE-FADE-4D2B-BCF6-4B058D73387A Q24234444-DDEC1C5E-C56A-4023-8343-465E7F97D84F Q24656570-AD01C59E-A1DC-4D2C-84C0-00ECED2136CC Q26751777-3AB7EF00-5830-4BA6-9139-428B169AC3B3 Q26775635-A0AAE462-F338-4DA4-B6D5-843FD24FD183 Q26779150-E8EA6DA0-1AF0-4373-8A58-53008192A2F3 Q26797836-55CE0602-50AA-4245-A4F1-5972B446E19A Q26822719-2D494BC4-4490-4C7B-A2FE-3D5BB8103E5A Q26999712-22CF22CC-74D2-495B-88F6-C6DD70085F6C Q27002598-1D3EE0C1-7C5F-45E0-96ED-DEEEAE060D2C Q27008984-AE2D034E-CDB2-490D-97A5-9475E6775914 Q27011623-1EC984CA-A491-4FB7-8085-F8739A039E90 Q27306083-0865D469-5307-4F53-AAD1-35842C864EDA Q27487009-FDCCEE33-657D-4F8F-8673-7F424BF0E3AF Q27693188-678A1D4A-02A5-41E5-963C-E721F315EC40 Q27928046-78833322-B0A8-4494-9673-7247B9D9E3AD Q28084820-6963FDF6-0F22-4FFE-955B-2023E851C19B Q28551711-DBDFD6C6-154B-419D-BFB6-EAA4D5818624 Q33801328-423078CF-9CC2-4AAE-9294-4829843F9FC3 Q33979916-B0BE2F6F-49CA-48C0-85D4-3290F9BB5509 Q34308129-BE49B1C2-B9BC-43A7-A598-FBA62B713A19 Q34382931-9670A7D3-AEA2-4C63-9894-2AC255468A66 Q34584862-29C5009A-5043-4224-9A25-5E478176DBD2 Q34615563-EDF72D90-B7C2-42B3-A7AB-256944BE2A9D Q34625734-78BA0C0A-B4CD-42BB-8BE8-C1336A79F025 Q34693445-B4039C72-C610-4EEF-96DD-E005770AE283 Q35043978-4CF0A916-F816-4C5D-80B5-5CD5BE551050 Q35126674-A383D692-9CA6-4340-BE5D-A0083557E8E5 Q35195132-A73FFC85-96FF-48B0-B024-83158AB08A1F Q35245231-6EED335A-997C-433F-8975-4FFDBA58F198 Q35259698-920F6897-5290-4D30-881A-4CBD37605D1D Q35354521-289041F2-676D-40C1-AF29-1E3A712BB2E1 Q35602284-BDFC69CD-90F8-4798-9738-CE79E94611F4 Q35778059-9D4325EB-3BF5-4E85-AFF5-2470548C5FEE Q36069081-70499863-FA4A-43F0-A8BB-7EBF13FC7677 Q36109563-A71A0A42-0AAE-4723-A132-51EE6F22BDDA Q36122356-D7B388F1-0400-461D-9213-1697BFEC08BA Q36216315-1EEC575E-483A-4B32-A692-4968B66A1A5E Q36260961-EB8239CA-6A77-401B-88EE-73C102AB958B Q36346851-B2F466B5-3346-44B6-A6DF-A47A16C88BDA

P2860

Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.

http://www.wikidata.org/entity/Q45396940

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Prevention of hepatitis B viru ...... om the large envelope protein.

@en

Prevention of hepatitis B viru ...... om the large envelope protein.

@nl

type

label

Prevention of hepatitis B viru ...... om the large envelope protein.

@en

Prevention of hepatitis B viru ...... om the large envelope protein.

@nl

prefLabel

Prevention of hepatitis B viru ...... om the large envelope protein.

@en

Prevention of hepatitis B viru ...... om the large envelope protein.

@nl

P1433

Q45396940-8A2C5FDC-6823-46E8-B018-C9D26163B837

P1476

Q45396940-A82143BB-5B32-4F9F-A5E6-23DE8AE63317

P2093

Q45396940-0606B41A-EAD7-4D41-8A1D-497770C8A736

Q45396940-2BF08396-E59C-498D-B2A1-475FC9D041F4

Q45396940-4A8D1547-4AE2-4427-92FF-DE73FF3E85DE

Q45396940-5F66601D-3FCE-4A81-8B4E-6204625ED5C3

Q45396940-649634B0-FC60-4B98-B823-058403CEDADF

Q45396940-6815129F-0622-4C5A-ADED-317F37BCE5E6

Q45396940-9C06027C-87BB-4A8A-8383-DF46C7803EB3

Q45396940-B4616ACA-4B81-4094-BCED-F4EDF63C7C42

Q45396940-E0563453-9692-4E2E-847C-A9C741B5A88E

Q45396940-E60A0C8A-DAAE-448E-8473-61DA77346274

P2860

Q45396940-4DA835E0-44C6-4846-8FDF-22744C3FB5F9

Q45396940-5C0B9432-61EF-4FDE-A1D8-09C1A28BED0A

Q45396940-85910B8E-01BD-4F05-A289-A7877172A074

P2888

Q45396940-9491E60A-DB1A-4702-97B3-9877002E20E8

P304

Q45396940-A776E764-B7EF-48EE-82EB-6EE92F856E9F

P31

Q45396940-647DCC3A-ED7D-43A8-9AE7-C7F007FD5128

P356

Q45396940-F60B5123-32F0-44CB-86AC-6EA26F77BF0F

P433

Q45396940-235AB3A0-6713-4703-AD80-12CD7C6B6033

P478

Q45396940-E98940D2-33F5-4301-B2FF-D67DFCA4BE5C

P50

Q45396940-04FF7305-09E2-40CC-BA7F-1C27B791A29B

Q45396940-A312952B-6519-483C-BCB0-39A2C6EFDE9C

P577

Q45396940-72C75060-A7C5-4AB2-9D70-DE10787C3FCD

P5875

Q45396940-8238BD6B-0092-4DD6-8FA2-C7E8AF2D54AC

P6179

Q45396940-A2D0F214-E089-43A9-AF8F-F8F24ABC507C

P698

Q45396940-B97AC7ED-B546-4C8C-AC47-0BB250BF679C

P356

P1433

Nature Biotechnology

P1476

Prevention of hepatitis B viru ...... rom the large envelope protein

@en

P2093

Berit Erbes

http://www.w3.org/2001/XMLSchema#string

Fritz von Weizsäcker

http://www.w3.org/2001/XMLSchema#string

Joerg Petersen

http://www.w3.org/2001/XMLSchema#string

Joerg-Matthias Pollok

http://www.w3.org/2001/XMLSchema#string

Lutz Fischer

http://www.w3.org/2001/XMLSchema#string

Marc Lütgehetmann

http://www.w3.org/2001/XMLSchema#string

Maura Dandri

http://www.w3.org/2001/XMLSchema#string

Stefan Seitz

http://www.w3.org/2001/XMLSchema#string

Stephan Urban

http://www.w3.org/2001/XMLSchema#string

Uwe Haberkorn

http://www.w3.org/2001/XMLSchema#string

P2860

Hepatitis B virus morphogenesis

Viral and cellular determinants involved in hepadnaviral entry

The complete mitochondrial genome of Tupaia belangeri and the phylogenetic affiliation of scandentia to other eutherian orders.

P2888

P304

335-341

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NBT1389

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5555280

http://www.w3.org/2001/XMLSchema#string

P6179

1008575164

http://www.w3.org/2001/XMLSchema#string

P698

18297057

http://www.w3.org/2001/XMLSchema#string